+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer



Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer



Journal of the American College of Cardiology 19(2): 394-401



Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy. To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects. Echocardiographic data from the experimental group of 21 patients (mean age 16 +/- 5 years) treated from 1.6 to 14.3 years (median 5.3) before this study with 27 to 532 mg/m2 of doxorubicin (mean 196) were compared with echocardiographic data from 12 normal age-matched control subjects. Graded dobutamine infusions of 0.5, 2.5, 5 and 10 micrograms/kg per min were administered. Echocardiographic Doppler studies were performed before infusion and after 15 min of infusion at each rate. Dobutamine infusion at 10 micrograms/kg per min was discontinued after six studies secondary to a 50% incidence rate of adverse symptoms. The most important findings were that compared with values in control subjects, end-systolic left ventricular posterior wall dimension and percent of left ventricular posterior wall thickening in doxorubicin-treated patients were decreased at baseline study and these findings were more clearly delineated with dobutamine stimulation. End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01). End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 039858256

Download citation: RISBibTeXText

PMID: 1732369

DOI: 10.1016/0735-1097(92)90497-b


Related references

Low-dose dobutamine stress echocardiography in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. European Heart Journal 22(Abstract Supplement): 540, September, 2001

Dobutamine stress test in long term childhood cancer survivors treated with doxorubicin. Journal of the American College of Cardiology 17(2 SUPPL A): 333A, 1991

Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer. Pediatrics International 48(3): 313-320, 2006

The role of dobutamine stress echocardiography in early diagnosis of cardiac toxicity in long-term survivors of asymptomatic children treated with anthracycline. Anadolu Kardiyoloji Dergisi 10(2): 154-162, 2010

Early diagnosis of anthracycline toxicity in asymptomatic long-term survivors: dobutamine stress echocardiography and tissue Doppler velocities in normal and abnormal myocardial wall motion. European Journal of Echocardiography 11(10): 814-822, 2011

Low-dose dobutamine echo stress test for the evaluation of cardiac function in asymptomatic childhood cancer survivors treated years before with anthracycline. European Heart Journal 19(ABST SUPPL ): 312, 1998

Is enalapril beneficial in doxorubicin-treated long-term survivors of childhood cancer?. Circulation 96(8 SUPPL ): I436, 10/21/97, 1997

Afterload reduction therapy in long term survivors of childhood cancer treated with doxorubicin. Circulation 84(4 SUPPL): II659, 1991

Comparative long-term prognostic value of dobutamine stress echocardiography versus dobutamine stress myocardial perfusion SPECT. Journal of the American College of Cardiology 43(5 Supplement A): 331A, March 3, 2004

Long-term prognostic value of dobutamine stress echocardiography versus dobutamine stress myocardial perfusion SPECT. Circulation 108(17 Supplement): IV-438, October 28, 2003

Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines. Pediatric Blood & Cancer 52(5): 631-636, 2009

Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. Journal of Clinical Oncology 20(23): 4517-4522, 2002

Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatric Research 39(3): 504-512, 1996

Values of high sensitive troponin T in long-term survivors of childhood cancer treated with anthracyclines. Clinica Chimica Acta; International Journal of Clinical Chemistry 441(): 29-32, 2015

Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study. Pediatric Blood & Cancer 54(4): 579-584, 2010